Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland

VärbamineFaas 2

Vanused 19 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06738303

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Strecker Cancer Center-Belpre, Belpre
Adena Regional Medical Center, Chillicothe
Ohio State University Comprehensive Cancer Center, Columbus
ja veel 22

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT03866382

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

University Hospitals Cleveland Medical Center, Cleveland

Värbamine

Vanused 18 ja vanemad · Mehed · Uuendatud 28. sept 2026 · NCT06496256

DESTINY-PANTUMOUR04

Research Site, Canton
Research Site, Maumee

VärbamineVaatlusuuring

Vanused 18–130 · Kõik sood · Uuendatud 25. sept 2026 · NCT07124000

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

University Hospitals Cleveland Medical Center, Cleveland

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07319871

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

University Hospitals Cleveland Medical Center ( Site 0043), Cleveland

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT06136650

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

University Hospitals Cleveland Medical Center, Cleveland

VärbamineFaas 1

Vanused 18 ja vanemad · Mehed · Uuendatud 25. sept 2026 · NCT07082920

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati
University Hospitals Cleveland Medical Center, Cleveland
ja veel 2

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 24. sept 2026 · NCT07028853

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Central Ohio Urology Group, Gahanna

VärbamineFaas 2/3

Vanused 18–100 · Mehed · Uuendatud 22. sept 2026 · NCT06780670

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Oncology Hematology Care Incorporated, Cincinnati
The Ohio State University, Columbus
Dayton Physicians LLC Dayton, Dayton

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 22. sept 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Urology Group - Solaris Network, Cincinnati
Central Ohio Urology Group, Gahanna

VärbamineFaas 3

Vanused 18–100 · Mehed · Uuendatud 22. sept 2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Research Site, Columbus

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 18. sept 2026 · NCT06952803

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 17. sept 2026 · NCT06925737

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland

VärbamineFaas 2

Vanused 18 ja vanemad · Mehed · Uuendatud 15. sept 2026 · NCT06150417

Investigation of Impact of AI on Prostate Cancer Workflow

Cleveland Clinic Foundation, Cleveland

Värbamine

Vanused 55–80 · Kõik sood · Uuendatud 15. sept 2026 · NCT07084779

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Oncology Hematology Care Incorporated, Cincinnati

VärbamineFaas 1

Vanused 18 ja vanemad · Mehed · Uuendatud 15. sept 2026 · NCT07493512

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

University Hospitals Cleveland, Cleveland

Värbamine

Vanused 18 ja vanemad · Mehed · Uuendatud 14. sept 2026 · NCT06511141

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Cleveland Clinic Akron General, Akron
UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
ja veel 27

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 10. sept 2026 · NCT05946213

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Solaris Health - The Urology Group, Cincinnati

VärbamineFaas 2

Vanused 18 ja vanemad · Mehed · Uuendatud 3. sept 2026 · NCT07005154

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Gabrail Cancer Center Research, Canton

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 3. sept 2026 · NCT07723248

The Vanguard Study: Testing a New Way to Screen for Cancer

Louis Stokes Cleveland VA Medical Center, Cleveland

VärbamineTerved vabatahtlikud oodatud

Vanused 45–75 · Kõik sood · Uuendatud 2. sept 2026 · NCT06995898

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Site, Cleveland
Research Site, Dayton

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 26. aug 2026 · NCT07611110

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Oncology Hematology Care Incorporated, Cincinnati

VärbamineFaas 1

Vanused 18 ja vanemad · Mehed · Uuendatud 21. aug 2026 · NCT04221542

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

The Ohio State University, Columbus
Taylor Cancer Research Center, Maumee

VärbamineFaas 1/2

Vanused 18 ja vanemad · Mehed · Uuendatud 20. aug 2026 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Good Samaritan Hospital - Cincinnati, Cincinnati
Bethesda North Hospital, Cincinnati
Ohio State University Comprehensive Cancer Center, Columbus

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 19. aug 2026 · NCT04423211

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

University Hospitals Cleveland Medical Center, Cleveland

VärbamineFaas 2

Vanused 18 ja vanemad · Mehed · Uuendatud 17. aug 2026 · NCT06842498

FOG-001 in Locally Advanced or Metastatic Solid Tumors

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
Cleveland Clinic, Cleveland

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. aug 2026 · NCT05919264

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

University of Cincinnati Medical Center, Cincinnati
The Ohio State University, Columbus

VärbamineFaas 1

Vanused 18–100 · Mehed · Uuendatud 13. aug 2026 · NCT05519449

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland

Värbamine

Vanused 19 ja vanemad · Mehed · Uuendatud 6. aug 2026 · NCT05610852

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

The Ohio State University, Columbus

VärbamineFaas 1

Vanused 18 ja vanemad · Mehed · Uuendatud 31. juuli 2026 · NCT06613100

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Cleveland Clinic Akron General, Akron
UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
ja veel 15

VärbamineFaas 3

Vanused 18 ja vanemad · Mehed · Uuendatud 14. juuli 2026 · NCT06592924

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Ohio State University Comprehensive Cancer Center, Columbus

VärbamineFaas 2

Vanused 18 ja vanemad · Mehed · Uuendatud 14. juuli 2026 · NCT05691465

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

The Ohio State University Comprehensive Cancer Center, Columbus

VärbamineFaas 1

Vanused 18 ja vanemad · Mehed · Uuendatud 9. juuli 2026 · NCT07103018

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland

VärbamineVaatlusuuring

Vanused 18 ja vanemad · Mehed · Uuendatud 7. juuli 2026 · NCT07406282

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.